Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma
Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
Phase II clinical trial on the combination of avelumab and axitinib for the treatment of
patients with recurrent glioblastoma (histologically confirmed WHO grade IV glioma), at
documented recurrence/progression following prior treatment with surgery, radiation therapy
and temozolomide.